



- (51) **International Patent Classification:**
A61P 31/14 (2006.01) *C07K 16/10* (2006.01)
- (21) **International Application Number:**
PCT/EP2021/063008
- (22) **International Filing Date:**
17 May 2021 (17.05.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/026,121 17 May 2020 (17.05.2020) US
- (71) **Applicant:** **ASTRAZENECA UK LIMITED** [GB/GB];
1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge CB2 0AA (GB).
- (72) **Inventors:** **ESSER, Mark**; c/o MedImmune, LLC, One
MedImmune Way, Gaithersburg, Maryland 20878 (US).
STEINHARDT, James; c/o AstraZeneca Pharmaceuticals
LP, One MedImmune Way, Gaithersburg, Maryland 20878
(US). **MCTAMNEY II, Patrick**; c/o MedImmune, LLC,
One MedImmune Way, Gaithersburg, Maryland 20878

(US). **LOO, Yueh-Ming**; c/o MedImmune, LLC, One
MedImmune Way, Gaithersburg, Maryland 20878 (US).
VARKEY, Reena M.; c/o MedImmune, LLC, One MedIm-
mune Way, Gaithersburg, Maryland 20878 (US). **DU, Qun**;
c/o MedImmune, LLC, One MedImmune Way, Gaithers-
burg, Maryland 20878 (US). **RAJAN, Saravanan**; c/o
AstraZeneca Pharmaceuticals LP, One MedImmune Way,
Gaithersburg, Maryland 20878 (US).

(74) **Agent:** **MACLEAN, Martin Robert** et al.; Mathys &
Squire, The Shard, 32 London Bridge Street, London SE1
9SG (GB).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) **Title:** SARS-COV-2 ANTIBODIES AND METHODS OF SELECTING AND USING THE SAME




Fig. 9

(57) **Abstract:** The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*